Broad genomic profiling was used in only 1 in 4 US patients with newly diagnosed metastatic cancer between 2020 and 2022, a new study reported. Although testing rates increased over this time period, ...
The Center for Molecular Oncology at NYU Langone Health's Perlmutter Cancer Center will soon launch a new protocol for patients diagnosed with early-stage and advanced cancers, developing new ...
CGP identifies TP53 and SMAD4 mutations as negative prognostic markers, while PTEN mutations correlate with improved survival in CRC patients. Despite no significant survival advantage, CGP-guided ...
New QIAseq panels launched for use on next-generation sequencers to boost analysis of over 700 genes for comprehensive genomic profiling in research and clinical applications Advancing key ...
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key ...
Strand Life Sciences, a global genomic profiling company that uses next generation sequencing technology to empower cancer care, today announced it will introduce its expanded StrandAdvantage ...
The company expands precision oncology portfolio with new Paletrra spatial proteomics platform "The debut of the PanTracer Family and Paletrra represents a significant milestone for NeoGenomics and a ...
Genetic and metabolic differences may increase aggressive early breast cancer risk in Latin American women with obesity, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback